Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics

Eur J Pharm Biopharm. 2013 May;84(1):1-20. doi: 10.1016/j.ejpb.2012.12.009. Epub 2013 Jan 8.

Abstract

Therapeutics such as nucleic acids, proteins/peptides, vaccines, anti-cancer, and other drugs have disadvantages of low bio-availability, rapid clearance, and high toxicity. Thus, there is a significant need for the development of efficient delivery methods and carriers. Injectable nanocarriers have received much attention due to their vast range of structures and ability to contain multiple functional groups, both within the bulk material and on the surface of the particles. Nanocarriers may be tailored to control drug release and/or increase selective cell targeting, cellular uptake, drug solubility, and circulation time, all of which lead to a more efficacious delivery and action of therapeutics. The focus of this review is injectable, targeted nanoparticle drug delivery carriers highlighting the diversity of nanoparticle materials and structures as well as highlighting current therapeutics and targeting moieties. Structures and materials discussed include liposomes, polymersomes, dendrimers, cyclodextrin-containing polymers (CDPs), carbon nanotubes (CNTs), and gold nanoparticles. Additionally, current clinical trial information and details such as trial phase, treatment, active drug, carrier sponsor, and clinical trial identifier for different materials and structures are presented and discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic / methods
  • Drug Carriers / administration & dosage*
  • Drug Delivery Systems / methods
  • Humans
  • Injections
  • Liposomes
  • Nanostructures / administration & dosage*
  • Neoplasms / diagnosis
  • Neoplasms / drug therapy

Substances

  • Drug Carriers
  • Liposomes